Benzinga | Sep 29, 2021 07:23AM EDT

Catalyst Biosciences' Lead Candidate Secures Orphan Drug Tag For Blood Clotting Disorder

* The FDA has granted Orphan Drug Disease Designation to Catalyst Biosciences Inc's (NASDAQ:CBIO) Marzeptacog alfa (activated), or MarzAA, for Factor VII Deficiency (FVIID).

* Factor VII deficiency is a blood clotting disorder that causes excessive or prolonged bleeding after an injury or surgery.

* MarzAA was previously granted Orphan drug and Fast Track Designations for Hemophilia A/B with inhibitors and Fast Track tag for FVIID.

* Related Link: Catalyst Biosciences Stock Moves Higher On Additional FDA Fast Track Tag For MarzAA

* Related content: Benzinga's Full FDA Calendar.

* Price Action: CBIO stock closed 2.81% lower at $4.50 on Tuesday.